Loading...
Loading...
PHAT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 31.7M |
| Operating I/L | -31.7M |
| Other Income/Expense | -9.3M |
| Interest Income | 0.3M |
| Pretax | -41.0M |
| Income Tax Expense | 9.6M |
| Net Income/Loss | -41.0M |
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of treatments for gastrointestinal diseases. The company holds the rights to vonoprazan, a potassium-competitive acid blocker (P-CAB) that inhibits stomach acid secretion. Vonoprazan is currently in Phase III clinical trials for erosive gastroesophageal reflux disease and is being studied in combination with antibiotics for Helicobacter pylori infection treatment.
